| Astellas–Adaptimmune: allogenic T-cell therapies, 202001– collab r+d CAR-T + TCR therapies with up to $897.5m for ADAP + up to $552.5m for Astellas |
2020-01-14 |
| Illumina–Roche: genomic cancer testing, 202001–201412 collab €na strategic alliance non-excl for NGS-based cancer testing for IVD + CDx |
2020-01-13 |
| Incyte–MorphoSys: tafasitamab, 202001– collab + ww excl license incl US co-commercialisation $750m upfront + $1.1b milestones |
2020-01-13 |
| MorphoSys–Incyte: investment, 202001 equity investment $150m in new ADSs at premium to share price as part of tafasitamab collab/license agreement |
2020-01-13 |
| EQRx–1AB Media: public relations, 202001 service existent by 1AB Media |
2020-01-12 |
| EQRx–Alphabet: investment, 202001 financing round Series A totalling $200m incl GV |
2020-01-12 |
| EQRx–Andreessen Horowitz: investment, 202001 financing round Series A totalling $200m incl a16z |
2020-01-12 |
| EQRx–Arboretum Ventures: investment, 202001 financing round Series A totalling $200m incl Arboretum Ventures |
2020-01-12 |
| EQRx–ARCH Venture: investment, 202001 financing round Series A totalling $200m incl ARCH Venture Partners |
2020-01-12 |
| EQRx–Casdin Capital: investment, 202001 financing round Series A totalling $200m incl Casdin Capital |
2020-01-12 |
| EQRx–Nextech: investment, 202001 financing round Series A totalling $200m incl Nextech |
2020-01-12 |
| EQRx–Section 32: investment, 202001 financing round Series A totalling $200m incl Section 32 |
2020-01-12 |
| EQRx–SEVERAL: investment, 202001 financing round Series A $200m with GV + ARCH Venture Partners + Andreessen Horowitz + Casdin Capital et al. |
2020-01-12 |
| Iovance–Cellectis: gene editing technology, 202001– collab + license ww excl for TILs in several cancer indications |
2020-01-12 |
| Dermira–Lilly: investment, 202001– acquisition $1.1b cash tender offer at $18.75/share ANNOUNCED |
2020-01-10 |
| Tyra Biosciences–Alta Partners: investment, 202001 financing round Series A totalling $50m incl co-lead investor Alta Partners |
2020-01-10 |
| Tyra Biosciences–Canaan Partners: investment, 202001 financing round Series A totalling $50m incl co-lead investor Canaan |
2020-01-10 |
| Tyra Biosciences–RA Capital Management: investment, 202001 financing round Series A totalling $50m incl co-lead investor RA Capital Management |
2020-01-10 |
| Tyra Biosciences–SEVERAL: investment, 202001 financing round Series A $50m co-led by Alta Partners + RA Capital + Boxer Capital et al. |
2020-01-10 |
| Tyra Biosciences–Tavistock: investment, 202001 financing round Series A totalling $50m incl co-lead investor Boxer Capital |
2020-01-10 |
| Almirall–23andMe: therapeutic antibodies, 202001– license ww to bispecific MAb blocking all 3 isoforms of IL-36 |
2020-01-09 |
| Element Biosciences–Fidelity: investment, 202001 financing round Series B totalling $80.3m incl new investor Fidelity Management and Research |
2020-01-09 |
| Element Biosciences–Foresite Capital: investment, 202001 financing round Series B totalling $80.3m incl existing investor Foresite Capital LLC |
2020-01-09 |
| Element Biosciences–JS Capital: investment, 202001 financing round Series B totalling $80.3m incl new investor JS Capital LLC |
2020-01-09 |
| Element Biosciences–Rockefeller: investment, 202001 financing round Series B totalling $80.3m incl existing investor Venrock |
2020-01-09 |
| Element Biosciences–SEVERAL: investment, 202001 financing round Series B $80.3m with Fidelity + JS Capital + Foresite Capital + Venrock |
2020-01-09 |
| Nurix Therapeutics–LifeSci: public relations, 202001 service existent by LifeSci Public Relations |
2020-01-09 |
| Sanofi–Nurix Therapeutics: protein degradation drugs, 202001– collab strategic ww $55m upfront + $2.5m milestones using DELigase platform |
2020-01-09 |
| NorthSea Therapeutics–BioGeneration Ventures: investment, 202001 financing round Series B totalling €36m incl existing + co-investor BGV |
2020-01-08 |
| NorthSea Therapeutics–Forbion: investment, 202001 financing round Series B totalling €36m incl existing + co-investor Forbion |
2020-01-08 |
| NorthSea Therapeutics–New Science Ventures: investment, 202001 financing round Series B totalling €36m incl existing + co-investor NSV |
2020-01-08 |
| NorthSea Therapeutics–Novo Group: investment, 202001 financing round Series B totalling €36m incl existing + co-investor Novo Seeds |
2020-01-08 |
| NorthSea Therapeutics–SEVERAL: investment, 202001 financing round Series B €36m led by new investor VenBio |
2020-01-08 |
| NorthSea Therapeutics–Sofinnova: investment, 202001 financing round Series B totalling €36m incl new + co-investor Sofinnova Investments |
2020-01-08 |
| NorthSea Therapeutics–VenBio: investment, 202001 financing round Series B totalling €36m incl new + lead investor VenBio Partners |
2020-01-08 |
| Novome Biosciences–Alexandria Real Estate: investment, 202001 financing round Series A totalling $33m incl co-investor Alexandria Venture Investments |
2020-01-07 |
| Novome Biotechnologies–5AM Ventures: investment, 202001 financing round Series A totalling $33m incl existing seed + co-investor 5AM Ventures |
2020-01-07 |
| Novome Biotechnologies–Alta Partners: investment, 202001 financing round Series A totalling $33m incl co-investor Alta Partners |
2020-01-07 |
| Novome Biotechnologies–DCVC: investment, 202001 financing round Series A totalling $33m incl lead investor DCVC Bio |
2020-01-07 |
| Novome Biotechnologies–Mayo Clinic: investment, 202001 financing round Series A totalling $33m incl co-investor Mayo Clinic |
2020-01-07 |
| Novome Biotechnologies–SEVERAL: investment, 202001 financing round Series A $33m led by DCVC Bio |
2020-01-07 |
| PharmAkea–Galecto Biotech: investment, 202001– merger €na with new Galecto Inc in US with operational HQ in Copenhagen ANNOUNCED |
2020-01-07 |
| VectivBio–Cowen: investment, 202001 1st financing round totalling $35m incl Cowen Healthcare Investors |
2020-01-07 |
| VectivBio–OrbiMed: investment, 202001 1st financing round totalling $35m incl OrbiMed |
2020-01-07 |
| VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. |
2020-01-07 |
| VectivBio–Tekla Capital: investment, 202001 1st financing round totalling $35m incl Tekla Healthcare Investors |
2020-01-07 |
| VectivBio–Versant Ventures: investment, 202001 1st financing round totalling $35m incl Versant Ventures |
2020-01-07 |
| VectivBio–WPP: public relations, 202001 service existent by Glover Park Group |
2020-01-07 |
| Integrated Biotherapeutics–Novo Group: investment, 202001 investment $3.9m in IBT Vaccines by Novo REPAIR Impact Fund |
2020-01-06 |
| Elpiscience–SEVERAL: investment, 201912 financing round Series B $100m led by Hyfinity Investments |
2019-12-28 |
| Xyphos Biosciences–Astellas: investment, 201912 acquisition 100% for $120m upfront + $545m milestones |
2019-12-27 |
| Xyphos Biosciences–Cooley: financial services, 201912 supply service Cooley legal counsel for acquisition of Xyphos by Astellas |
2019-12-27 |
| Xyphos Biosciences–Locust Walk: financial services, 201912 supply service Locust Walk financial advisor for acquisition of Xyphos by Astellas |
2019-12-27 |
| Codexis–LHA Investor Relations: public relations, 201912 service existent IR by LHA Investor Relations |
2019-12-23 |
| Roche–Codexis: DNA ligase, 201912 royalty bearing ww license to include EvoT4 DNA ligase in NA sequencing products + workflows |
2019-12-23 |
| Nabriva–Sam Brown: public relations, 201912 service existent by Sam Brown Inc |
2019-12-20 |
| Nabriva–SEVERAL: investment, 201912 registered direct offering $20m with 13.8m pairs ordinary share + warrant at $1.45/pair to institutional investors |
2019-12-20 |
| Savara–SEVERAL: investment, 201912– private placement $26.8m (with potential total proceeds of $75m) to institutional investors leb by Bain Capital LS |
2019-12-20 |
| CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance |
2019-12-19 |
| Forma Therapeutics–Cormorant Asset Management: investment, 201912 financing round Series D totalling $100m incl co-investor Cormorant Asset Management |
2019-12-19 |
| Forma Therapeutics–Janus Henderson: investment, 201912 financing round Series D totalling $100m incl co-investor Janus Henderson Investors funds |
2019-12-19 |
| Forma Therapeutics–OTHER: investment, 201912 financing round Series D totalling $100m incl undisclosed healthcare investment fund as co-investor |
2019-12-19 |
| Forma Therapeutics–RA Capital Management: investment, 201912 financing round Series D totalling $100m incl lead investor RA Capital Management |
2019-12-19 |
| Forma Therapeutics–Samsara BioCapital: investment, 201912 financing round Series D totalling $100m incl co-investor Samsara BioCapital |
2019-12-19 |
| Forma Therapeutics–SEVERAL: investment, 201912 financing round Series D $100m led by RA Capital Management |
2019-12-19 |
| Forma Therapeutics–Stern IR: public relations, 201703 service existent Stern IR is investor contact |
2019-12-19 |
| Forma Therapeutics–Wellington Management: investment, 201912 financing round Series D totalling $100m incl co-investor Wellington Management |
2019-12-19 |
| Genmab–CureVac: mRNA-based antibody therapeutics, 201912– collab research + license agreem 5y $10m upfront using CureVac mRNA + Genmab Ab technologies |
2019-12-19 |
| Kinnate Biopharma–Eshelman Ventures: investment, 201912 financing round Series B totalling $74.5m incl existing investor Eshelman Ventures |
2019-12-19 |
| Kinnate Biopharma–Foresite Capital: investment, 201912 financing round Series B totalling $74.5m incl existing investor Foresite Capital |
2019-12-19 |
| Kinnate Biopharma–Nextech Invest: investment, 201912 financing round Series B totalling $74.5m incl new investor Nextech Invest Ltd |
2019-12-19 |
| Kinnate Biopharma–OrbiMed: investment, 201912 financing round Series B totalling $74.5m incl new investor OrbiMed |
2019-12-19 |
| Kinnate Biopharma–SEVERAL: investment, 201912 financing round Series B $74.5m from OrbiMed + Nextech Invest + Vida Ventures + Foresite + Eshelman |
2019-12-19 |
| Kinnate Biopharma–Vida Ventures: investment, 201912 financing round Series B totalling $74.5m incl new investor Vida Ventures LLC |
2019-12-19 |
| Promega–Merck (DE): CRISPR technology, 201912– license to CRISPR IP io from Merck to Promega to develop CRISPR-edited cell lines |
2019-12-19 |
| BC Platforms–SEVERAL: investment, 201912 financing round Series C $15m led by Iqvia + incl Debiopharm Innovation Fund + Tesi |
2019-12-18 |
| Deerfield–Duke Univ: translational research, 201912–2029 collab establishm Four Points Innovation up to $130m from Deerfield to finance Duke projects |
2019-12-18 |
| Epirium Bio–Adams Street Partners: investment, 201912 financing round Series A totalling $85m incl co-investor Adams Street Partners |
2019-12-18 |
| Epirium Bio–ARCH Venture: investment, 201912 financing round Series A totalling $85m incl co-lead investor ARCH Venture Partners |
2019-12-18 |
| Epirium Bio–Bluebird Ventures: investment, 201912 financing round Series A totalling $85m incl co-investor Bluebird Ventures |
2019-12-18 |
| Epirium Bio–Longevity Fund: investment, 201912 financing round Series A totalling $85m incl co-investor The Longevity Fund |
2019-12-18 |
| Epirium Bio–Longitude Capital: investment, 201912 financing round Series A totalling $85m incl co-lead investor Longitude Capital |
2019-12-18 |
| Epirium Bio–SEVERAL: investment, 201912 financing round Series A $85m co-led by Longitude Capital + ARCH Venture Partners |
2019-12-18 |
| Epirium Bio–Temasek: investment, 201912 financing round Series A totalling $85m incl co-investor Vertex Ventures HC |
2019-12-18 |
| KCR CRO–Veeva Systems: clinical research software, 201912– supply adoption of Veeva Vault CTMS by KCR |
2019-12-18 |
| ArcherDx–ArrowMark Partners: investment, 201912 financing round Series C totalling $55m incl new + co-investor ArrowMark Partners |
2019-12-17 |
| ArcherDx–Boulder Ventures: investment, 201912 financing round Series C totalling $55m incl existing + co-investor Boulder Ventures |
2019-12-17 |
| ArcherDx–Driehaus Capital: investment, 201912 financing round Series C totalling $55m incl new + co-investor Driehaus Capital Management |
2019-12-17 |
| ArcherDx–Longwood Fund: investment, 201912 financing round Series C totalling $55m incl existing + co-investor Longwood Fund |
2019-12-17 |
| ArcherDx–PBM Capital: investment, 201912 financing round Series C totalling $55m incl existing + co-investor BPM Capital + affiliates |
2019-12-17 |
| ArcherDx–Perceptive Advisors: investment, 201912 financing round Series C totalling $55m incl existing + lead investor Perceptive Advisors |
2019-12-17 |
| ArcherDx–Redmile Group: investment, 201912 financing round Series C totalling $55m incl new + co-investor Redmile Group |
2019-12-17 |
| ArcherDx–Sands Capital: investment, 201912 financing round Series C totalling $55m incl existing + co-investor Sands Capital |
2019-12-17 |
| ArcherDx–SEVERAL: investment, 201912 financing round Series C $55m led by Perceptive Advisors |
2019-12-17 |
| ArcherDx–Soleus Capital: investment, 201912 financing round Series C totalling $55m incl new + co-investor Soleus Capital |
2019-12-17 |
| Seer–aMoon: investment, 201912 financing round Series D totalling $55m incl lead investor aMoon Fund |
2019-12-17 |
| Seer–SEVERAL: investment, 201912 financing round Series D $55m led by aMoon + incl T Rowe Price + all existing plus other new investors |
2019-12-17 |
| Seer–T Rowe Price Associates: investment, 201912 financing round Series D totalling $55m incl funds + accounts advised by T Rowe Price |
2019-12-17 |
| Flagship Pioneering–WPP: public relations, 201912 service existent by Ogilvy |
2019-12-16 |
| Promethera–SEVERAL: investment, 201912 financing round Series D extension €7.5m bringing total round to €47.2m |
2019-12-16 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lse-life-sciences-europe-com.jpg)
Date![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
